Oruka Therapeutics (ORKA) Announces $200 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
TD Cowen Starts Oruka Therapeutics (ORKA) at Buy
September 16, 2024 5:31 AM EDTTD Cowen analyst Tyler Van Buren initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating.
The analyst comments "Oruka is backed by sophisticated mAb engineering and both ORKA-001 and ORKA-002 have a high PoS by targeting the same... More
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
September 12, 2024 4:47 PM EDTJefferies analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target of $40.00.
The analyst comments "We initiate ORKA at BUY and see high probability of success for two YTE modified "long-acting" enhanced antibodies for... More
